HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.


Professor Christoph Zielinski

Professor Zielinski is Director of the Comprehensive Cancer Center at Medical University Vienna and the General Hospital in Vienna, Austria, and is Scientific Director of the newly founded Vienna Cancer Center. Since 1999, he is President of the Central European Cooperative Oncology Group (www.cecog.org) which is conducting clinical trials and maor educational activities in 23 countries of Central and Southeastern Europe.

Professor Zielinski completed his medical training at the University Hospital Vienna and began his career with a position as a research fellow at the Cancer Research Center at Tufts University, Boston, USA. From 2004 to 2017 he was chairman of the Department of Medicine I and its Clinical Division of Oncology of the Medical University Vienna – General Hospital. His recent clinical research activities cover a wide range of cancer therapies, with particular focus on clinical trials, breast and lung cancer research and treatment and development of targeted drugs. He has published env. 600 original papers and reviews in peer-review journals and many books.

His h-Index is 59 and the citations of papers authored by him exceed 16.000.

Prof. Zielinski is Editor in Chief of the peer review open-access internet journal “ESMO Open – Cancer Horizons” which is one of two scientific journals of the European Society for Medical Oncology published by the BMJ group.

In 2013, Professor Zielinski received a “Dr. h.c.” degree from Titu Maiorescu University in Bucharest.

Professor Zielinski is a member of the European Society for Medical Oncology (ESMO) where he served on the Executive Board and as Chair of the Fellowships and Awards Committee from 2014-2017. He was Local Officer of the ESMO Annual Meeting 2012 and the ECC Meeting 2015. Prof. Zielinski is a Honorary Member of the Polish Society for Clinical Oncology and also member of the Austrian Society for Hematology and Oncology, the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the Chinese Society for Clinical Oncology (CSCO).

 

Professor Ursula Wiedermann

Chief Scientific Officer

Professor Wiedermann is Professor of Vaccinology and Head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University Vienna. Currently she also has an appointment as Visiting Professor at the University in Göteborg, Sweden. She has more than 100 peer-reviewed publications and is frequently performing presentations at national and international conferences. Professor Wiedermann was the Principal Investigator for the preclinical development of HER-Vaxx and together with Prof. Zielinski´s Division the Phase I clinical trial of HER-Vaxx in metastatic breast cancer patients was performed. Furthermore she has led the design of the Phase II study for gastric cancer due to commence in 2015.

Professor Wiedermann had studied Medicine in Vienna, Austria. Between 1990-1995 she entered a PhD-program in Sweden at the Institute of Clinical Immunology at the University Gothenburg, focusing her research on mucosal immunity and vaccination. Back in Vienna she continued her research career at the University of Vienna concentrating on mucosal vaccination against allergic diseases. After her habilitation (venia docendi) in 1999 she founded the research group “Mucosal Immunity and Vaccination”. In 2001 she finished her medical training as specialist for “Immunology” and “Specific Prophylaxis and Tropical Hygiene”. At the Institute of Specific Prophylaxis and Tropical Medicine she enlarged her research areas to vaccine development against infectious diseases and tumours, and focused on clinical vaccine trials to study immune responsiveness and immune failures upon vaccination. In 2004 she became Head of the Institute of Specific Prophylaxis and Tropical Medicine of the Medical University Vienna and in 2006 she was assigned Professor for Vaccinology at the Medical University Vienna. She is a member of the Supreme Board of Health and the Chairman of the National Committee of Immunization Practice of the Austrian Ministry of Health. Since 2009 she is Speaker of the newly founded Centre for Geographic Medicine at the Medical University Vienna.

 

Dr Neil Segal

Dr Segal is an oncologist at the Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer centre in the US. His research interests focus on the development of new therapies and more specifically, ways to use the immune system to treat cancer. This parallels the approach taken with Imugene’s HER-Vaxx vaccine, which aims to activate the patient’s immune system to produce its own antibodies. Dr Segal has further clinical expertise in colorectal, pancreatic, bile duct and other gastrointestinal cancers. He holds a Doctorate of Medicine and Philosophy from University of the Witwatersrand in South Africa.

 

Dr. Yelena Janjigian

Dr. Yelena Janjigian is a medical oncologist at the Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer centre in the US.  Dr. Janjigian specializes in the treatment of malignancies of the gastrointestinal tract, including esophagus and stomach cancers. Her research focuses on the development of new treatments for patients with esophagus and stomach cancers, and is particularly interested in finding ways to select the best treatments for persons with cancer based on the molecular characteristics of their tumor specimens. Dr. Janjigian runs clinical and translational studies designed to develop a better prevention, early diagnosis, staging, and treatment strategies. She is the Principal Investigator on a number of clinical trials at Memorial Sloan Kettering.  Dr. Janjigian received her doctorate in medicne from New York University School of Medicine.   Dr. Janjigian holds board certifications for internal medicine and medical oncology.

 

Professor Peter Schmid

Prof Schmid is Chair of Cancer Medicine at the prestigious Barts Cancer Institute at Queen Mary University London.  He is also Clinical Director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. He leads the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre.

Prof Schmid’s specialist cancer interests are breast and lung cancer, cancer immune therapy and early drug development. 

He has successfully led more than 20 national and international academic clinical studies and is a member of several national and international cancer organizations and research groups.  He has authored or co-authored 165 publications and published a book on the management of bone metastases currently in its third edition. 

 
 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551